#ANCA #vasculitis is not created equally REVEAL cohort 588 ANCA Initial & 12 months #BVAS (activity index) mean ⬇️BVAS over 1 yr in all groups #GPA #MPA #eGPA 5yr survival not = over time ⬆️survival in eGPA & GPA vs MPA #POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS

#EULAR2025 Abstr#POS0325 Immunosuppressant-free is not only confined to CAR-T. Our cohort study in #SLE: 20% patients were “Super-Responder” (>3yrs response) inc. 7% IS-free after one Rituximab cycle. Non-European, APS & shorter disease duration predicted super-response @RheumNow https://t.co/nPIYpGoynR

Is RA just one disease? No, & increasingly more efforts to subgroup RA on diff levels Simple approach - derived phenotypes map (independent of ACPA): - to broad histopath - to MTX response Omics is good, but still need to do the simple stuff better! #EULAR2025 OP0328 @RheumNow https://t.co/a8Vl7Kcjso

In axSpA patients with persistent pain, digital behavioral therapy (ACT-app) improved MPI pain-related life interference (β −0.36, 95% CI −0.73 to 0.01) and affective distress (β −0.40, 95% CI −0.84 to 0.003) vs standard of care (SOC). 43% completed full program. NPS 5.8. https://t.co/T6i9jkjcoU

In AS (n=91,493), D2T defined as ≥2 b/tsDMARD classes plus elevated CRP. Risk factors: HLA-B27+ (OR 1.30), obesity (OR 1.20), depression (OR 1.22). D2T group had higher CRP (55.7 mg/L), BMI (31.1), and more EAMs (IBD, psoriasis, uveitis). Female predominance (56.9%)Abstract https://t.co/EHCt5wq4ot

#EULAR2025 Abstr#OP0199 Validation of effective & safe HCQ blood levels monitoring (750-1150ng/mL) to guide optimal dose. Particulary important in those with CKD Stage =>3 as considered high risk of toxicity. Next steps: wider availability & cost-effectiveness analysis @RheumNow https://t.co/WoVFolrmPA

#EULAR2025 Abstr#OP0200 Which social determinant of health in Europe affect #SLE outcomes so that these can be improved? Registry in Sweden showed factors associated with damage/mortality: - Lower income & education, - No partner - On sick leave/disability benefits @RheumNow https://t.co/hgEfJzoqNg

#EULAR2025 Abstr#OP0201 Achieving treatment targets (LLDAS and/or DORIS) is more prognostically important. In Phase 3 RCT, compared with PBO+SOC, Dapirolizumab+SOC resulted in higher rates of achievement and time in LLDAS and DORIS. LLDAS plateud after WK28 in PBO+SOC @RheumNow https://t.co/3Zd3jjx984

#EULAR2025 Abstr#OP0198 Long-term extension study of Phase 2 #SLE showed efficacy of Upadacitinib and UPA + Elsubrutinib were maintained through to Week 104. Those who switched from PBO at WK48 to UPA + ELSU also improved. No VTE or MACE. Is add-on ELSU really needed? @RheumNow https://t.co/x8NbAtsHh0